GlobeNewswire Inc.··Hagens BermanImmunityBio Faces Class Action Over FDA Warning on Cancer Drug Claims
ImmunityBio (IBRX) shares plunged 21% after FDA warning letter citing misleading efficacy claims about immunotherapy drug Anktiva. Class action lawsuit underway with May 26 deadline.
IBRXinvestor lossessecurities class action